|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 October 2012 |
|
Main ID: |
NCT00611611 |
|
Date of registration:
|
28/01/2008 |
|
Primary sponsor: |
|
|
Public title:
|
BLYS and IFN in SLE
|
|
Scientific title:
|
BLyS and IFN Responses to Antigen Challenge in Human SLE |
|
Date of first enrolment:
|
October 2007 |
|
Target sample size:
|
39 |
|
Recruitment status: |
Completed |
|
URL:
|
http://clinicaltrials.gov/show/NCT00611611 |
|
Study type:
|
Observational |
|
Study design:
|
Observational Model: Case Control, Time Perspective: Prospective
|
|
|
Countries of recruitment
|
|
United States
| | | | | | | |
|
Contacts
|
|
Name:
|
Robert H Carter, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
University of Alabama at Birmingham |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- ACR lupus criteria
- 18
Exclusion Criteria:
- chronic infection or cancer
- pregnancy
Age minimum:
19 Years
Age maximum:
65 Years
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Systemic Lupus Erythematosus
|
|
Intervention(s)
|
|
Biological: fluzone
|
|
Biological: pneumovax
|
|
Primary Outcome(s)
|
|
change in specific antibodies in response to vaccine
[Time Frame: 2 weeks]
|
|
Secondary Outcome(s)
|
|
change in BLyS after vaccination
[Time Frame: 2 weeks]
|
|
change in IFN after vaccination
[Time Frame: 2 weeks]
|
|
Secondary ID(s)
|
|
F060217005
|
|
NIH R21 AI069363
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|